CHUGAI-PHARMACEUTICAL
4.2.2019 02:02:14 CET | Business Wire | Press release
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Hemlibra® , a treatment for hemophilia A created by Chugai, for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. The CHMP has also adopted a positive opinion for additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with factor VIII inhibitors.
“We are thrilled that Hemlibra is expected to be approved shortly for people with severe hemophilia A without inhibitors in the Europe Union (EU). Also, I’m very pleased that people in the EU with hemophilia A will soon be offered multiple options of Hemlibra’s dosing interval regardless of their inhibitor expression,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Osamu Okuda. “Hemlibra is co-promoted by Chugai and Roche in Germany, France, and the United Kingdom, as is the case with the anti-rheumatic agent RoActemra® . We are committed to pursue our efforts in collaboration with Roche so that Hemlibra may further contribute to the treatment of hemophilia A.”
This positive opinion is based on results from two Phase III studies HAVEN 3 (NCT02847637) and HAVEN 4 (NCT03020160), conducted jointly with Roche and Genentech. HAVEN 3 study was conducted to evaluate the reduction of bleed rate of Hemlibra subcutaneous injection once a week and once every two weeks in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. HAVEN 4 study was conducted to evaluate efficacy, safety, and pharmacokinetics of Hemlibra subcutaneous injection every four weeks in people with hemophilia A (12 years of age or older), with and without inhibitors to factor VIII.
In Japan, Chugai obtained regulatory approval for Hemlibra from the Ministry of Health, Labour and Welfare in December 2018 for an additional indication of prophylactic treatment for people with hemophilia A without inhibitors to factor VIII, as well as for additional dosage and administration as a biweekly or every four-week treatment for people with hemophilia A with inhibitors to factor VIII.
References
Chugai’s HEMLIBRA®
Receives Regulatory Approval from U.S. FDA
for Hemophilia A without Inhibitors
Press release issued on October
5, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20181005100000_553.html
Chugai’s HEMLIBRA®
Subcutaneous Injection Receives Approval
for Hemophilia A without Inhibitors and Extension of Dosing Interval --
HEMLIBRA is now available for Hemophilia A, regardless of inhibitor
status –
Press release issued on December 21, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20181221153002_580.html
About Severe Hemophilia A
People with severe hemophilia A is defined as the condition with less than 1 % of factor VIII levels. Hemophilia A affects around 320,000 people worldwide, 1,2 approximately 50-60% of whom are expected to have a severe form of the disorder3 .
1) WFH. Guidelines for the management of haemophilia. 2012 [Internet;
cited 2018 July]. Available from:
http://www1.wfh.org/publications/files/pdf-1472.pdf
.
(as of February 1, 2019)
2) Berntorp E, Shapiro AD. Modern
haemophilia care. The Lancet 2012; 370:1447-1456.
3) Marder VJ, et
al. Hemostasis and Thrombosis. Basic Principles and Clinical Practice.
6th Edition, 2013. Milwakee, Wisconsin. Lippincott Williams and Wilkin.
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
Additional information is
available on the internet at https://www.chugai-pharm.co.jp/english
.
Trademarks used or mentioned in this release are protected by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190203005041/en/
Contact:
For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Tomoko Shimizu Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp
For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com
For European media Chugai Pharma France SAS Nathalie Leroy Tel: +33-1-56-37-05-21 E-mail: pr@chugai.eu
For Taiwanese media Chugai Pharma Taiwan Ltd. Susan Chou Tel: +886-2-2715-2000 E-mail: pr@chugai.com.tw
For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Toshiya Sasai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 13:05:00 CET | Press release
Speaking at the 2026 Singapore FinTech Festival, Ant International’s CEO Peng Yang argued that our settlement infrastructure needs to evolve beyond today’s four-party payments model to assign effectively roles and responsibilities.Ant International processed the equivalent of 1.1 trillion USD on its WhaleRTP blockchain settlement network in the last 12 months in collaboration with 23 leading global banks; expected to double in 2027.He also said that agentic economy needs to rest on a stronger multi-rail, multi-modal and multi-asset trust layer, and that good AI solutions design can power a new, more inclusive globalization project by putting the little guys on a level playing field. At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedi
NIQ Appoints Danny Lange and Chris Tung to Board of Directors19.11.2026 12:45:00 CET | Press release
Appointments add deep AI leadership and Greater China and Asia Pacific operating expertise to NIQ’s Board NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that Danny Lange and Chris Tung have been appointed to its Board of Directors, effective Nov. 18, 2026. Lange brings more than three decades of technology leadership, including senior roles building and scaling artificial intelligence and machine learning capabilities at Google, Unity, Uber, Amazon and Microsoft. Tung brings extensive operating, consumer and digital commerce experience across Greater China and Asia Pacific through leadership roles at Shangri-La Asia, Alibaba, PepsiCo, L’Oréal and other global businesses. Together, their experience strengthens the Board’s perspective as NIQ advances its AI strategy and expands its impact across global markets. “Danny and Chris bring expertise that directly aligns with where NIQ is going,” said Jim Peck, Executive Chairman and Chief Executive Officer of N
Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 119.11.2026 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/FkwyWrnNgoveMhBfJS2NCC/We7ydUWZPZM5Wf4zVRNZnZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation f
Pretium Expands Real Estate Debt Platform19.11.2026 12:00:00 CET | Press release
Addition of Hilltop Capital Partners Enables the Firm to Deploy Capital to the U.K. Housing Market Pretium, a specialized investment firm with approximately $70 billion in assets under management, today announced it is expanding its residential real estate debt platform, further enabling the flow of capital to real estate investors, developers and homebuilders. Since launching its residential debt platform in December 2024, Pretium has lent approximately $8 billion for the purpose of new housing construction and the renovation of existing homes. Building on its existing model, Pretium is adding the team from Hilltop Capital Partners (“Hilltop”), a specialized U.K.-based institutional capital advisor, investment manager and principal lender, to its vertically integrated residential real estate platform. Led by Paul Oberschneider and Tiger Craft, Hilltop has grown into a leading platform for residential development finance across the U.K since its founding in 2019. “The U.K. faces a hous
SRM and Ridgemont Equity Partners Announce Strategic Partnership to Accelerate Next Phase of Growth19.11.2026 12:00:00 CET | Press release
SRM and Ridgemont Continue a 30+ Year Track Record of Helping Banks, Credit Unions, and Fintech Companies Unlock Growth, Innovation, and Operational Efficiency Strategic Resource Management (SRM), a trusted, tech-enabled advisory firm serving financial institutions globally, today announced a strategic investment from Ridgemont Equity Partners, a middle market private equity investor. Building on over three decades of experience serving financial institutions and fintechs, this recapitalization aims to further strengthen SRM’s capabilities, talent, systems, and resources. Brad Downs, Chief Executive Officer and Chairman, and SRM’s existing leadership team will continue to lead the company into its next phase of growth. “SRM is a market-leading advisory firm with a strong reputation and proven track record, and is led by a very experienced executive team with a passion for delivering measurable results and meaningful business impact. SRM is an excellent fit with our experience in Busine
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
